logo

Compugen Ltd (CGEN)



Trade CGEN now with
  Date
  Headline
7/30/2020 7:26:40 AM Compugen Q2 Net Loss $6.2 Mln Or $0.08/shr Vs Net Loss $6.0 Mln Or $0.10/shr Last Year
7/30/2020 7:00:00 AM Compugen Reports Second Quarter 2020 Results (Press Release)
6/12/2020 10:52:13 AM Stock Alert: Compugen Jumps 9%
6/1/2020 7:08:06 AM Compugen: FDA Clears IND Application For Phase 1/2 Of COM701 With Bristol Myers Squibb's Opdivo And TIGIT Inhibitor
5/27/2020 7:02:38 AM Compugen Doses First Patient In COM701 Phase 1 Monotherapy Expansion Cohort
5/6/2020 7:17:25 AM Compugen Q1 Net Loss $7.1 Mln Or $0.10/shr Vs. Net Loss $8.4 Mln Or $0.14/shr Last Year
4/27/2020 6:03:11 AM Compugen Presents Data Update From Ongoing Phase 1 Trial Of COM701 At 2020 AACR Virtual Annual Meeting
4/22/2020 8:30:45 AM European Patent Office Grants Compugen A New Patent Forcomposition Of COM701 Or Backup Antibodies For Cancer
4/14/2020 7:02:42 AM Compugen To Present Data Update On COM701 Phase 1 Clinical Trial At The 2020 AACR Virtual Annual Meeting
4/6/2020 7:01:41 AM Compugen Announces First Patient Dosed In COM902 Phase 1 Trial For Patients With Advanced Malignancies
3/17/2020 7:06:13 AM Compugen Announces Closing Of Public Offering Of 8.33 Mln Ordinary Shares At $9/Shr
3/12/2020 6:06:56 AM Compugen Prices Public Offering Of 8.33 Mln Ordinary Shares At $9.00 Per Share
3/9/2020 7:12:31 AM Compugen Announces Updated Clinical Data From Ongoing COM701 Phase 1 Study
2/20/2020 7:31:21 AM Compugen Q4 Net Loss $6.5 Mln Or $0.10/Shr Vs Loss Of $9.4 Mln Or $0.16/Shr Last Year